TP6.1.6 The management of pancreatic fluid collections with AXIOS stenting in Belfast HSCT

Abstract

Abstract Aims To assess the viability of using lumen-apposing self-expandable AXIOS stents, inserted under endoscopic ultrasound guidance, in the management of pancreatic fluid collections (PFCs) within the Belfast Health and Social Care Trust. Methods Data for all AXIOS stents inserted endoscopically between May 2016 and July 2019 were included. Electronic care records (ECR) and Radiology reports were reviewed for each patient. PFCs were categorised into walled-of pancreatic necrosis (WOPN) and pseudocysts, and the number of repeat procedures, OGDs with lavage, or the need for definitive surgery were recorded. The timeframe to surgery and whether PFCs recollected was also noted. Results 45 AXIOS stents were inserted for PFCs in the audit period. n = 17 (37.8%) were for WOPN, n = 28 (62.2%) for pseudocysts. Mean duration of stenting was 38 ± 19.7 days. n = 11 (35.6%) patients were readmitted for sepsis with stent in situ, and n = 16 (35.6%) required OGD and lavage for stent blockage (n = 11 WOPN; n = 5 pseudocyst). n = 2 (4.4%) stents accidentally dislodged during lavage necessitating surgical removal. n = 4 (8.9%) patients required a second AXIOS stent following removal, n = 2 (4.4%) required CT guided drainage and n = 8 (17.8%) ultimately required surgical intervention. Conclusions Despite some drawbacks, including the need for intermittent OGD and lavage to maintain patency, AXIOS stenting appears to be effective first-line management for PFCs. Our audit showed they were successful in 71% of cases, requiring no further intervention. In PFCs that do require surgical management, AXIOS stenting may represent an effective bridge to surgery allowing for patient optimization before definitive care.